Article
Biogen stands to lose billions in Tecfidera sales next year, analyst says after new court ruling
Rating:
0.0
Views:
115
Likes:
1
Library:
1
Defending its blockbuster MS drug Tecfidera from generics hasn't been easy for Biogen lately, and the painful trend continued this week with a court ruling that clears the way for more copycat drugs to launch—and siphon off most of its $3.3 billion in U.S. sales, an analyst said.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value